Pretreatment with Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, Reduces Passive Systemic Anaphylaxis in a Murine Model

There is an unmet need for therapeutics able to prevent serious allergic reactions including food allergy and anaphylaxis. Bruton’s tyrosine kinase (Btk) has been shown to be critical for allergen reactivity in mast cells and basophils by transducing high affinity IgE receptor crosslinking signals into cellular activation and mediator release. We sought to determine the effect of ibrutinib, an FDA-approved, irreversible Btk inhibitor for B cell malignancies, on systemic anaphylaxis using a murine model.